Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
  • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
  • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
  • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
  • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C231/00—Preparation of carboxylic acid amides
  • C07C231/06—Preparation of carboxylic acid amides from nitriles by transformation of cyano groups into carboxamide groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
  • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
  • C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
  • C07C233/10—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
  • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
  • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
  • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
  • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/07—Optical isomers

Definitions

• the present invention relates to novel methods for the preparation of glutamic acid derivatives and intermediates thereof. Glutamic acid derivatives are useful as metalloproteinase inhibitors.
• Metalloproteinases including matrix metalloproteinases and aggrecanases, are known to have a role in the breakdown of connective tissue.
• Matrix metalloproteinases constitute a superfamily of proteolytic enzymes that are genetically related and capable of degrading almost all the constituents of extracellular matrix and basement membrane that restrict cell movement.
• Aggrecanases are members of the ADAMTS (A disintegrin and metalloproteinase with thrombospondin motifs) family of proteins.
• Aggrecanase-1 and aggrecanase-2 have been designated ADAMTS-4 and ADAMTS-5, respectively (Tang B.L., IntJBiochem Cell Biol 2001, 33, 33-44).
• the ADAMTS family is involved in cleaving aggrecan, a cartilage component also known as the large aggregating chondroitin sulphate proteoglycan (Abbaszade I. et al., J Biol Chem 1999, 274, 23443-23450), procollagen processing (Colige A. et al., Proc Natl Acad Sd USA 1997, 94, 2374-2379), angiogenesis (Vazquez F. et al., J Biol Chem 1999, 274, 23349-23357), inflammation (Kuno K. et n ⁇ ., JBiol Chem 1997, 272, 556-562) and tumor invasion (Masui T. et al., J Biol Chem 1997, 272, 556-562). MMPs have been shown to cleave aggrecan as well.
• the loss of aggrecan has been implicated in the degradation of articular cartilage in arthritic diseases, for example osteoarthritis is a debilitating disease which affects at least 30 million Americans. Degradation of articular cartilage and the resulting chronic pain can severely reduce quality of life. An early and important characteristic of the osteoarthritic process is loss of aggrecan from the extracellular matrix, resulting in deficiencies in the biomechanical characteristics of the cartilage.
• MMPs and aggrecanases are known to play a role in many disorders in which extracellular protein degradation or destruction occurs, such as cancer, asthma, chronic obstructive pulmonary disease ("COPD”), atherosclerosis, age-related macular degeneration, myocardial infarction, corneal ulceration and other ocular surface diseases, hepatitis, aortic aneurysms, tendonitis, central nervous system diseases, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia, and periodontal diseases.
• COPD chronic obstructive pulmonary disease
• atherosclerosis age-related macular degeneration
• myocardial infarction corneal ulceration and other ocular surface diseases
• hepatitis hepatitis
• aortic aneurysms tendonitis
• the invention provides novel methods as described in the appended claims for preparing a compound of formula (I) and intermediates thereof, or pharmaceutically acceptable salt thereof,
• R 1 is phenyl, heteroaryl, biphenyl, bicyclic aryl, tricyclic aryl, bicyclic heteroaryl, or tricyclic heteroaryl, each optionally substituted with one or more of R 5 or R 6 , and when R 1 is substituted with more than one of R 5 or R 6 , the substituents can be identical or different;
• R 2 is hydrogen, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(CH 2 )nRii, -OH, or -0-(C 1 -C 6 ) alkyl;
• R 7 and R 8 are each independently hydrogen, (Ci-C 6 ) alkyl, aryl, heteroaryl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, cycloalkyl, -(CHbVaryl, or -(CH 2 ) n -heteroaryl; or R 7 and Rg together with the nitrogen atom to which they are attached may form a five- to seven-membered cyclic group containing up to 3 heteroatoms each independently selected from N 5 O, or S;
• Ri 3 is halogen, -0-(C]-C 6 ) alkyl, -CO 2 H, -OH, -CF 3 , hydrogen, (Ci-C 6 ) alkyl, aryl, heteroaryl, (C 2 -Ce) alkenyl, (C 2 -C O ) alkynyl, cycloalkyl, cycloalkyl substituted with -OH 3 aryl substituted with -NH 2 , aryl substituted with -0-(C 1 -C 6 ) alkyl, -(CH 2 ) n -aryl, or -(CH 2 ) n -heteroaryl;
• Ri 7 and Ri 8 are each independently hydrogen, halogen, -CN, -OCF 3 , -CF 3 , -NO 2 , (Ci-C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, aryl, heteroaryl, cycloalkyl, - (CHa) n R n , or -O-(C r C 6 )alkyl; Rn is aryl, heteroaryl, or cycloalkyl; and n is O, 1, 2, 3, or 4.
• the invention provides glutamic acid derivatives and intermediates thereof, or pharmaceutically acceptable salt thereof prepared by such novel methods.
• alkyl refers to a substituted or unsubstituted saturated aliphatic hydrocarbon chain and includes, but is not limited to, straight and branched chains containing from 1 to 12 carbon atoms, or in some instances, from 1 to 6 carbon atoms, unless explicitly specified otherwise.
• alkyl methyl, ethyl, propyl, isopropyl, butyl, i-butyl and t-butyl are encompassed by the term "alkyl.”
• (Ci-C 6 )-alkyl includes straight ahd branched chain aliphatic groups having from 1 to 6 carbons. Specifically included within the definition of "alkyl” are those aliphatic hydrocarbon chains that are optionally substituted.
• the number of carbon atoms as used in the definitions herein refers to carbon backbone and carbon branching, but does not include carbon atoms of the substituents, such as alkoxy substitutions and the like.
• alkenyl refers to a substituted or unsubstituted ethylenically unsaturated hydrocarbon chain and includes, but is not limited to, straight and branched chains having 2 to 8 carbon atoms and containing at least one double bond. In one embodiment, the alkenyl moiety has 1 or 2 double bonds. Such alkenyl moieties may exist in the E or Z conformations and the compounds of this invention include both conformations. (C 2 -C 6 ) alkenyl includes a 2 to 6 carbon straight or branched chain having at least one carbon- carbon double bond.
• alkenyl those aliphatic hydrocarbon chains that are optionally substituted.
• a heteroatom, such as O, S or N, attached to an alkenyl is not attached to a carbon atom that is bonded to a double bond.
• alkynyl refers to a hydrocarbon moiety containing at least one carbon-carbon triple bond.
• (C 2 -Ce) alkynyl includes a 2 to 6 carbon straight or branched chain having at least one carbon-carbon triple bond.
• cycloalkyl refers to a monocyclic, bicyclic, tricyclic, fused, bridged, or spiro monovalent saturated hydrocarbon ring system, wherein the carbon atoms are located inside or outside of the ring system, e.g., of 3-15 carbon atoms. Any suitable ring position of the cycloalkyl moiety may be covalently linked to the defined chemical structure.
• cycloalkyl moieties include, but are not limited to, cyciopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, cyclohexyl ethyl, cycloheptyl, norbornyl, adamantyl, spiro[4.5]decanyl, and homologs, isomers, and the like.
• C 3 -C O cycloalkyl includes monocyclic, saturated rings of 3 to 6 carbons.
• Heteroaryl refers to a 5 to 6 membered aromatic heterocyclic ring which contains from 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur atoms in the ring and may be fused with a carbocyclic or heterocyclic ring at any possible position (e.g. fused to one or more carbocyclic or heterocyclic rings, each having 5-8 ring atoms, the fused heterocyclic ring containing from 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur atoms in the ring).
• heteroaryl groups include, but are not limited to, furanyl, furazanyl, homopiperazinyl, imidazolinyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrimidinyl, phenanthridinyl, pyranyl, pyrazinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyrimidinyl, pyrr ⁇ linyl.
• thiadiazinyl thiadiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, and triazolyl.
• Heterocycloalkyl refers to a saturated ring or ring system containing carbon atoms and from 1 to 4 heteroatoms selected from N, O, and S, each of the ring or ring system being 5 to 7- ⁇ nembered.
• heterocycloalkyl groups include, but are not limited to, azepanyl, azetidinyl, aziridinyl, imidazolidinyl, morpholinyl, oxazolidinyl, piperazinyl, piperidinyl, pyrazolidinyl, pyrrolidinyl, quinuclidinyl, tetrahydrofuranyl, and thiomorpholinyl.
• aryl refers to an aromatic carbocyclic ring system, e.g., of from 6 to 14 carbon atoms such as phenyl, which may be optionally substituted.
• An aryl group may be fused with a carbocyclic or heterocyclic ring at any possible position (e.g. fused to one or more carbocyclic or heterocyclic rings, each having 5-8 ring atoms, the fused heterocyclic ring containing from 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur atoms in the ring).
• Phenyl refers to a substituted or unsubstituted phenyl group.
• biphenyl refers to two phenyl groups connected at one carbon site on each ring.
• biasing refers to two aryl groups connected at one carbon site on each ring.
• bicyclic aryl refers to two fosed carbocyclic groups, wherein one or both of the carbocyclic groups is aromatic.
• a bicyclic aryl can contain from 8 to 12 ring atoms.
• tricyclic aryl refers to three fused carbocyclic groups, wherein two or three of the carbocyclic groups is aromatic.
• a tricyclic aryl can contain from 13 to 18 ring atoms.
• bicyclic heteroaryl refers to two fused cyclic groups, wherein one or both of the cyclic groups is aromatic and contains one to four heteroatoms selected from O, S, and N.
• a bicyclic heteroaryl can contain from 8 to 12 ring atoms, and from 1 to 3 heteroatoms selected from O, N, and S in each ring.
• tricyclic heteroaryl refers to three fused cyclic groups, wherein two or three of the cyclic groups is aromatic and at least one aromatic group contains 1 to 4 heteroatoms selected from O, S, and N.
• a tricyclic aryl can contain from 13 to 18 ring atoms, and from 1 to 3 heteroatoms selected from O, N, and S in each ring.
• an optionally substituted moiety may be substituted with one or more substituents, examples of which are as illustrated herein.
• moieties When such moieties are substituted, for example, they may typically be mono-, di-, tri- or persubstituted.
• a halogen substituent include 1-bromo vinyl, 1-fiuoro vinyl, 1 ,2-difluoro vinyl, 2,2-difluorovinyl, 1,2,2-trifluorovinyl, 1,2-dibromo ethane, 1,2 difluoro ethane, l-fluoro-2-bromo ethane, CF 2 F 3 , CF2CF 2 CF 3 , and the like.
• halogen includes bromine, chlorine, fluorine, and iodine.
• connection points are not depicted.
• an atom or compound is described to define a variable, it is understood that it is intended to replace the variable in a manner to satisfy the valency of the atom or compound.
• both carbon atoms form a part of the ring in order to satisfy their respective valences.
• divalent substituents it is understood that they are not limited to the order listed, for example, as used in this specification "OCH 2 " encompasses CH 2 O and OCH 2 .
• amine protecting group refers to a moiety that temporarily blocks an amine reactive site in a compound. Generally, this is done so that a chemical reaction can be carried out at another reactive site in a multifunctional compound or to otherwise stabilize the amine. In one embodiment, an amine protecting group is selectively removable by a chemical reaction.
• An exemplary amine protecting group is a 9-fluorenylmethoxycarbonyl protecting group.
• Another exemplary amine protecting group is an organoxycarbonyl group, i.e. where the amine is protected as a carbamate.
• Carbamates include, without limitation, t-butyl carbamate, methyl carbamate, ethyl carbamate, 2,2,2-trichloroethyl carbamate, 2-(trirnethylsilyl)ethyl carbamate, l,l-dimethyl-2,2,2-trichloroethyl carbamate, benzyl carbamate, p- methoxybenzyl carbamate, p-nitrobenzylcarbamate, p-bromobenzyl carbamate, p- chlorobenzyl carbamate, and 2,4-dichlorobenzyl carbamate.
• carboxylic acid protecting group refers to a moiety that temporarily blocks a carboxylic acid reactive site in a compound. Generally, this is done so that a chemical reaction can be carried out at another reactive site in a multifunctional compound or to otherwise stabilize the carboxylic acid.
• a carboxylic acid protecting group is selectively removable by a chemical reaction.
• An exemplary carboxylic acid protecting group is an alkyl ester protecting group, such as a tert-butyl ester. See, Greene and Wuts, Protecting Groups in Organic Synthesis, Third Edition, John Wiley & Sons (1999).
• metalloproteinase-related disorder refers to a condition for which it would be beneficial to modulate activity of the metalloproteinase.
• exemplary metalloproteinase-related disorders include, without limitation, arthritic disorders, osteoarthritis, cancer, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, corneal ulceration and other ocular surface diseases, hepatitis, aortic aneurysms, tendonitis, central nervous system diseases, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia, and periodontal diseases.
• metalloproteinase modulator refers to a compound that is capable of modulating the expression of a metalloproteinase.
• a metalloproteinase modulator may enhance metalloproteinase expression.
• a metalloproteinase modulator may also be an inhibitor of a metalloproteinase.
• isolated and purified refers to an isolate that is separate from other components of a reaction mixture or a natural source.
• the isolate contains at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 98% of the compound or pharmaceutically acceptable salt of the compound by weight of the isolate.
• a compound of the invention includes a pharmaceutically acceptable salt thereof.
• pharmaceutically acceptable salt refers to a salt of an acid and a basic nitrogen atom of a compound of the present invention.
• Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, hydrochloride, bromide, hydrobromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, napthalenesulfonate, propionate, succinate, fumarate, maleate, malonate, mandelate, malate, phthalate, and pamo
• the term "substantially free of its corresponding opposite enantiomer” as used herein means that the compound contains no more than about 10% by weight of its corresponding opposite enantiomer. In other embodiments, the compound that is . substantially free of its corresponding opposite enantiomer contains no more than about 5%, no more than about 1%, no more than about 0.5%, or no more than about 0.1% by weight of its corresponding opposite enantiomer.
• An enantiomer that is substantially free of its corresponding opposite enantiomer includes a compound that has been isolated and purified or has been prepared substantially free of its corresponding opposite enantiomer.
• tautomer refers to compounds produced by the phenomenon wherein a proton of one atom of a molecule shifts to another atom. See,
• ACN is acetonitrile
• Boc is t-butyl carbamate
• Bu is butyl
• DMF is dimethylformamide
• DMSO dimethylsulfoxide
• Et is ethyl
• HPLC high pressure liquid chromatography
• IPA is isopropyl alcohol
• Me is methyl
• NMM is N-methylmorpholine
• NMR nuclear magnetic resonance
• TBME is t-butyl methyl ether
• TFA is trifluoroacetic acid
• THF is tetrahydrofuran.
• the compounds or pharmaceutically acceptable salts of compounds of the present invention can contain an asymmetric carbon atom and some of the compounds or pharmaceutically acceptable salts of compounds of the invention can contain more than one asymmetric centers or no asymmetric centers, and can thus give rise to optical isomers, diastereomers and racemic mixtures. While depicted with or without respect to a particular asymmetric center in the compounds or pharmaceutically acceptable salts of compounds of the present invention, the present invention includes such optical isomers and diastereomers, as well as racemic and resolved, enantiomerically pure R and S stereoisomers, and also other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof.
• a stereoisomer is provided, it can in some embodiments be provided substantially free of its corresponding opposite enantiomer.
• the compounds and pharmaceutically acceptable salts of compounds of the present invention can exist as tautomers. Such tautomers can be transient or isolatable as a stable product. These tautomers are within the scope of the present invention.
• Prodrugs of the compounds or pharmaceutically acceptable salts of compounds are also within the scope of the present invention.
• Ri is phenyl, heteroaryl, biphenyl, bicyclic aryl, tricyclic aryl, bicyclic heteroaryl, or tricyclic heteroaryl, each optionally substituted with one or more of Rs or Re, and when Ri is substituted with more than one of Rs or R 6 , the substituents can be identical or different;
• R 2 is hydrogen, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(CHa) n R 1 ,, -OH, or -0-(Ci-C 6 ) alkyl;
• R 7 and Rs are each independently hydrogen, (C 1 -C 6 ) alkyl, aryl, heteroaryl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, cycloalkyl, -(CH 2 ) n -aryl, or -(CH 2 ) n -heteroaryl; or R 7 and Rg together with the nitrogen atom to which they are attached may form a five- to seven-membered cyclic group containing up to 3 heteroatoms each independently selected from N, O, or S;
• Rn is aryl, heteroaryl, or cycloalkyl
• R 13 is halogen, -0-(Ci-C 6 ) alkyl, -CO 2 H, -OH, -CF 3 , hydrogen, (C r C 6 ) alkyl, aryl, heteroaryl, (C 2 -C 6 ) alkenyl, (C 2 -C O ) alkynyl, cycloalkyl, cycloalkyl substituted with -OH, aryl substituted with -NH 2 , aryl substituted with -0-(C 1 -C 6 ) alkyl, -(CH 2 ) n -aryl, or -(CH 2 ) n -heteroaryl;
• R 16 is (C 1 -C 6 ) alkyl
• R 17 and Ri 8 are each independently hydrogen, halogen, -CN, -OCF3, -CF 3 , -NO 2 , (Ci-C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, aryl, heteroaryl, cycloalkyl, - (CHa) n Rn, or -O-(C,-C 6 )alkyl;
• PG 1 is an amine protecting group
• PG2 is a carboxylic acid protecting group; and n is O, 1, 2, 3, or 4.
• the compounds of formula (I) through (XIV) include enantiomerically pure compounds and/or sensitive protecting groups which may be labile to certain reaction conditions.
• the present invention provides methods for preparing such compounds substantially free of their corresponding opposite enantiomers and without disturbing the protecting groups when such groups are needed.
• the present invention is directed to a method of preparing a compound of formula (I),
• organometallic compound selected from the group consisting of isopropyl magnesium halide, isopropyl lithium, diisopropyl zinc and isopropyl zinc halide, preferably isopropyl magnesium chloride, to provide a compound of formula (X);
• step (e) converting the compound having formula (XIV) or its pharmaceutically acceptable salt into the compound of formula (I) or a pharmaceutically acceptable salt thereof; and optionally step (e) further comprises the following steps:
• the present invention is directed to a method for preparing a compound of the formula (XIII),
• the present invention is directed to a method for preparing a compound of the formula (XIV) or a pharmaceutically acceptable. salt thereof,
• the present invention is directed to a method for preparing a compound of formula (XIIIa),
• organometallic compound selected from the group consisting of isopropyl magnesium halide, isopropyl lithium, diisopropyl zinc and isopropyl zinc halide, preferably isopropyl magnesium chloride, to provide a compound of formula (Xa); and
• the present invention is directed to a method for preparing a compound of formula (XIVa), or a pharmaceutically acceptable salt thereof,
• the present invention is directed to a method aring a compound of formula (Ia),
• organometallic compound selected from the group consisting of isopropyl magnesium halide, isopropyl lithium, diisopropyl zinc and isopropyl zinc halide, preferably isopropyl magnesium chloride, to provide a compound of formula (Xa);
• step (e) converting the compound having formula (XIVa) or its pharmaceutically acceptable salt into the compound of formula (Ia) or a pharmaceutically acceptable salt thereof; and optionally step (e) further comprises the following steps:
• the present invention is directed to a compound of formula (XIIIa)
• the present invention is directed to a compound of formula (XIII),
• organometallic compound selected from the group consisting of isopropyl magnesium halide, isopropyl lithium, diisopropyl zinc and isopropyl zinc halide, preferably isopropyl magnesium chloride, to provide a compound of formula (X); and
• the present invention is directed to a compound of formula (XIV), or a pharmaceutically acceptable salt thereof,
• organometallic compound selected from the group consisting of isopropyl magnesium halide, isopropyl lithium, diisopropyl zinc and isopropyl zinc halide, preferably isopropyl magnesium chloride, to provide a compound of formula (X); and
• the present invention is directed to a compound of formula (I),
• organometallic compound selected from the group consisting of isopropyl magnesium halide, isopropyl lithium, diisopropyl zinc and isopropyl zinc halide, preferably isopropyl magnesium chloride, to provide a compound of formula (X);
• step (e) converting the compound having formula (XIV) or its pharmaceutically • acceptable salt into the compound of formula (I) or a pharmaceutically acceptable salt thereof; and optionally step (e) further comprises the following steps:
• organometallic compound selected from the group consisting of isopropyl magnesium halide, isopropyl lithium, diisopropyl zinc and isopropyl zinc halide, preferably isopropyl magnesium chloride, to provide a compound of formula (Xa); and
• the present invention is directed to a compound of formula (XIVa), or a pharmaceutically acceptable salt thereof,
• organometallic compound selected from the group consisting of isopropyl magnesium halide, isopropyl lithium, diisopropyl zinc and isopropyl zinc halide, preferably isopropyl magnesium chloride, to provide a compound of formula (Xa);
• the present invention is directed to a compound of formula (Ia),
• organometallic compound selected from the group consisting of isopropyl magnesium halide, isopropyl lithium, diisopropyl zinc and isopropyl zinc halide, preferably isopropyl magnesium chloride, to provide a compound of formula (Xa); ⁇
• step (e) converting the compound having formula (XIVa) or its pharmaceutically acceptable salt into the compound of formula (Ia) or a pharmaceutically acceptable salt thereof; and optionally step (e) further comprises the following steps:
• the compounds and pharmaceutically acceptable salts of compounds of the present invention can be prepared using a variety of methods starting from commercially available compounds, known compounds, or compounds prepared by known methods.
• General synthetic routes to many of the compounds of the invention are included in the following schemes. It is understood by those skilled in the art that protection and deprotection steps not shown in the Schemes may be required for these syntheses, and that the order of steps may be changed to accommodate functionality in the target molecule.
• Scheme 2 demonstrates the synthesis of the compound of formula (XIV) from the compound of formula (VIII).
• the compound of formula (VIII) is commercially available or can be prepared by a person of ordinary skill in the art.
• the compound of formula (VIII) can react with an organometallic compound such as isopropyl magnesium halide, isopropyl lithium, diisopropyl zinc and isopropyl zinc halide, preferably isopropyl magnesium chloride, to give a compound of formula (X).
• organometallic compound such as isopropyl magnesium halide, isopropyl lithium, diisopropyl zinc and isopropyl zinc halide, preferably isopropyl magnesium chloride, to give a compound of formula (X).
• Preferred halides for said organometallic compound are bromide and chloride.
• Treatment of the compound of formula (X) with at least one acid, such as sulfuric acid, or glacial acetic acid and sulfuric acid, followed by chloroacetonitrile provides a compound of formula (XIII).
• the acid treatment of the benzylic alcohol of formula (X) affords a carbocation of formula (XI), which rearranges to a carbocation of formula (XII).
• the benzylic alcohol of formula (X) can be converted to a corresponding styrene derivative (i.e., the elimination product of the hydroxyl group) before forming the carbocation of formula (XII) upon treating with at least one acid.
• the carbocation of formula (XII) can further react with chloroacetonitrile to give a chloroacetamide of formula (XIII), which can be converted to a tertiary amine of formula (XIV) by reacting with a base and/or thiourea, preferably just thiourea.
• Said base preferably is an aqueous base, such as sodium or potassium hydroxide.
• the tertiary amine of formula (XIV) can be further converted a pharmaceutically acceptable salt by reacting with a pharmaceutically acceptable acid, such as hydrochloric acid.
• Scheme 3 describes a synthesis of a compound of formula (I) from the compound of formula (XFV), or a pharmaceutically acceptable salt thereof.
• the amine of formula (XIV) can be coupled with (i) a compound of formula (IV); or (ii) a compound of formula (IVb), or (iii) a compound of formula (II), in the presence of a base and/or a peptide coupling reagent, to afford a compound of formula (V).
• Non-limiting examples of the peptide coupling reagent include N,N'-Dicyclohexylcarbodiimide [DCC], l-(3- Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride [EDCI], and those recited in Bodansky and Bodansky, Practice of Peptide Synthesis, 2nd ed., Springer- Verlag, Berlin (1994), the disclosure of which is incorporated herein by reference in its entirety.
• Treatment of the compound of formula (V) with an amine base can cleave the amine protecting group of PGj to provide a compound of formula (VI).
• amine bases may be used, including for example, diethylamine, piperidine, morpholine, dicyclohexylamine, p-dimethylaminopyridine, or diisopropylethylamine in a solvent, such as acetonitrile or DMF.
• a solvent such as acetonitrile or DMF.
• RiCOCl in the presence of a base affords a compound of formula (VII).
• the carboxylic acid protecting group of the compound of formula (VII) can be cleaved to give the compound of formula (I).
• the cleavage step can be carried out using TFA, NaOH, LiOH, potassium carbonate, or the like.
• Scheme 5 further describes the synthesis of a compound of formula (Ia) from a compound of formula (XIVa) or pharmaceutically acceptable salt thereof, using a method analogous to that described in Scheme 3.
• the carboxylic acid protecting group of the compound of formula (Vila) can be cleaved to give the compound of formula (Ia).
• the cleavage step can be achieved by using TFA.
• the cleavage step can be carried out via hydrolysis by using a base such as NaOH, LiOH, potassium carbonate, or the like. Applicants do not wish to be bound by any mechanism through which the deprotection step is achieved.
• In-process samples Dissolve 1-2 drops of reaction mixture in 2 mL of 50:50 acetonitrile-.water containing 1-2 drops of acetic acid.
• a 500-ml, 4-neck roundbottom flask was equipped with a mechanical agitator, temperature probe, nitrogen inlet, and 125-ml liquid addition funnel.
• a solution of l-(4-fluorophenyl)-2-methyl-l-propanol in acetic acid (135 grams, 127 mL) as prepared in the first step.
• Glacial acetic acid (90 grams, 85.8 ml) was then charged to the flask.
• the resulting mixture was cooled to about 0 - 5 0 C.
• the 125-ml liquid addition funnel was charged with 32% sulfuric acid (83.7 grams). The sulfuric acid was added dropwise to the reaction mixture.
• reaction temperature was maintained at about 0 — 10 0 C.
• reaction mixture was allowed to warm to about 20 — 25°C over about 40 minutes, and then stirred at about 20 - 25 0 C for over 20 hr.
• the reaction mixture was then transferred over about 55 minutes into a 500-ml round bottom flask containing chloroacetonitrile (63.0 grams).
• the reaction temperature was maintained between about 20 — 3O 0 C.
• the resulting mixture was allowed to stir at about 20 — 3O 0 C for about 3 hr. Completion of the reaction was assessed by HPLC.
• the mixture was transferred over 20 minutes into a 3-liter round bottom flask containing a mixture of water (470 ml), toluene (62 ml), and heptane (62 ml) at about 0 — 5°C. During the transfer, the drown-out mixture was maintained between about 0 — 10 0 C. After the transfer was completed, the resulting two-phase mixture was agitated for about five minutes, and then allowed to phase separate. The lower aqueous phase was removed, and then the organic phase was washed successively with 5% sodium chloride solution, followed by water.
• Heptane (178 grams) was added to the organic phase, and then the mixture was distilled under reduced pressure to remove approximately 53 ml of distillate. The batch was allowed to slowly cool to about 20 - 25 0 C. When the mixture reached about 29 0 C, the product began to crystallize. The mixture was allowed to stir at about 20 — 25 0 C for about 16 hours, and then cooled to about 0 — 5°C. The mixture was filtered and the product was washed with heptane. The product was dried to give chloro-N-[2-(4-fiuorophenyl)-l,l-dimethylethyl]acetamide as a white solid (60.11 grams, 96.4% HPLC area).
• NMR data 1.37, 1.45 - s, 6H, CH 3 ; 2.10 - m, 2H, CH 2 ; 2.35-2.60 - m, 2H, CH 2 ; 2.80-3.10 - d, 2H, CH 2 ; 4.80 - q, IH, CH; 6.80-7.80 - m, 13H, Ph; 7.90 - s, 2H, NH.

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Physical Education & Sports Medicine (AREA)
• Pulmonology (AREA)
• Diabetes (AREA)
• Immunology (AREA)
• Rheumatology (AREA)
• Cardiology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Heart & Thoracic Surgery (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Transplantation (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Ophthalmology & Optometry (AREA)
• Gastroenterology & Hepatology (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Endocrinology (AREA)
• Emergency Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Pyrrole Compounds (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (2)

Family

ID=38610555

Family Applications (1)

Country Status (20)

Cited By (1)

Families Citing this family (3)

Family Cites Families (3)

• 2007
  • 2007-05-30 TW TW096119313A patent/TW200808715A/zh unknown
  • 2007-05-30 AR ARP070102333A patent/AR061420A1/es unknown
  • 2007-05-30 PE PE2007000671A patent/PE20080312A1/es not_active Application Discontinuation
  • 2007-05-31 CN CNA2007800201259A patent/CN101460449A/zh active Pending
  • 2007-05-31 WO PCT/US2007/012814 patent/WO2007143014A2/en not_active Ceased
  • 2007-05-31 EP EP07795533A patent/EP2024326A2/en not_active Withdrawn
  • 2007-05-31 AU AU2007254960A patent/AU2007254960A1/en not_active Abandoned
  • 2007-05-31 BR BRPI0712233-0A patent/BRPI0712233A2/pt not_active IP Right Cessation
  • 2007-05-31 CA CA002653463A patent/CA2653463A1/en not_active Abandoned
  • 2007-05-31 RU RU2008146043/04A patent/RU2008146043A/ru not_active Application Discontinuation
  • 2007-05-31 KR KR1020087032134A patent/KR20090016503A/ko not_active Withdrawn
  • 2007-05-31 MX MX2008015396A patent/MX2008015396A/es unknown
  • 2007-05-31 JP JP2009513267A patent/JP2009539766A/ja not_active Withdrawn
  • 2007-06-01 PA PA20078728901A patent/PA8728901A1/es unknown
  • 2007-06-01 US US11/809,426 patent/US20080119670A1/en not_active Abandoned
• 2008
  • 2008-11-18 NO NO20084839A patent/NO20084839L/no not_active Application Discontinuation
  • 2008-11-25 IL IL195513A patent/IL195513A0/en unknown
  • 2008-12-01 CR CR10475A patent/CR10475A/es not_active Application Discontinuation
  • 2008-12-01 ZA ZA200810201A patent/ZA200810201B/xx unknown
  • 2008-12-02 EC EC2008008933A patent/ECSP088933A/es unknown

Also Published As

Similar Documents

Legal Events